In a large-scale, international, multicenter, phase 1/1b trial, treatment of patients with advanced solid tumors with the B7H3-targeting antibody–drug conjugate YL201 was safe and showed preliminary clinical efficacy.
- Yuxiang Ma
- Yunpeng Yang
- Hongyun Zhao
